Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension

Life Sciences

Volumn 76, Issue 3, 2004, Pages 281-292

  Watanabe, Hiroshi ^a   Kosuge, Kazuhiro ^a   Nishio, Shinichiro ^a   Yamada, Hiroshi ^a   Uchida, Shinya ^a   Satoh, Hiroshi ^a   Hayashi, Hideharu ^a   Ishizaki, Takashi ^b   Ohashi, Kyoichi ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Diltiazem; HMG CoA reductase inhibitor; Pharmacodynamic interaction; Pharmacokinetic interaction; Simvastatin

Indexed keywords

CALCIUM ANTAGONIST; DILTIAZEM; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ADD ON THERAPY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIVER FUNCTION; MALE; MONOTHERAPY; SIDE EFFECT;

ADMINISTRATION, ORAL; AREA UNDER CURVE; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DILTIAZEM; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIPIDS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; SIMVASTATIN; TREATMENT OUTCOME;

EID: 7644239838     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2004.06.022     Document Type: Article

References (30)

1. D.R. Abernethy, J.B. Schwartz, and E.L. Todd Diltiazem and desacetyldiltiazem analysis in human plasma using high-performance liquid chromatography: Improved sensitivity without derivation Journal of Chromatography 342 1985 216 220
2. M. Arnadottir, L.O. Eriksson, H. Thysell, and J.D. Karkas Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin Nephron 65 1993 410 413
3. N.E. Azie, D.C. Brater, P.A. Becker, D.R. Jones, and S.D. Hall The interaction of diltiazem with lovastatin and pravastatin Clinical Pharmacology and Therapeutics 64 1998 369 377
4. M. Chaffman, and R.N. Brogden Diltiazem. A review of its pharmacological properties and therapeutic efficacy Drugs 29 1985 387 454
5. J.L. Goldstein, and M.S. Brown Regulation of the mevalonate pathway Nature 343 1990 425 430
6. A.M. Gotto Jr. Risk factor modification: rationale for management of dyslipidemia American Journal of Medicine 104 1998 6S 8S
7. K.L. Gould, S.W. Casscells, L.M. Buja, and D.C. Goff Non-invasive management of coronary artery disease. Report of a meeting at the University of Texas Medical School at Houston Lancet 346 1995 750 753
8. L. Hansson, T. Hedner, P. Lund-Johansen, S.E. Kjeldsen, L.H. Lindholm, J.O. Syvertsen, J. Lanke, U. de Faire, B. Dahlof, and B.E. Karlberg Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study Lancet 356 2000 359 365
9. D.R. Jones, J.C. Gorski, M.A. Hamman, B.S. Mayhew, S. Rider, and S.D. Hall Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation Journal of Pharmacology and Experimental Therapeutics 290 1999 1116 1125
10. K.T. Kivistö, T.S. Lamberg, T. Kantola, and P.J. Neuvonen Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole Clinical Pharmacology and Therapeutics 62 1997 348 354
11. K. Kosuge, Y. Jun, H. Watanabe, M. Kimura, M. Nishimoto, T. Ishizaki, and K. Ohashi Effects of CYP3A4 inhibition by diltiazem on pharmacokinetics and dynamics of diazepam in relation to CYP2C19 genotype status Drug Metabolism and Disposition 29 2001 1284 1289
12. M. Matsuzaki, T. Kita, H. Mabuchi, Y. Matsuzawa, N. Nakaya, S. Oikawa, Y. Saito, J. Sasaki, K. Shimamoto, and H. Itakura Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia Circulation Journal 66 2002 1087 1095
13. E. Molden, P.W. Johansen, G.H. Bøe, S. Bergan, H. Christensen, H.E. Rugstad, H. Rootwelt, L. Reubsaet, and G. Lehne Pharmacokinetics of diltiazem and its metabolites in relation to CYP2D6 genotype Clinical Pharmacology and Therapeutics 72 2002 333 342
14. O. Mousa, D.C. Brater, K.J. Sunblad, and S.D. Hall The interaction of diltiazem with simvastatin Clinical Pharmacology and Therapeutics 67 2000 267 274
15. K. Nakagawa, and T. Ishizaki Therapeutic relevance of pharmacogenetic factors in cardiovascular medicine Pharmacology and Therapeutics 86 2000 1 28
16. P.J. Neuvonen, T. Kantola, and K.T. Kivisto Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole Clinical Pharmacology and Therapeutics 63 1998 332 341
17. L. Pichard, G. Gillet, I. Fabre, I. Dalet-Beluche, C. Bonfils, J.P. Thenot, and P. Maurel Identification of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the N-demethylation of diltiazem Drug Metabolism and Disposition 18 1990 711 719
18. T. Prueksaritanont, L.M. Gorham, B. Ma, L. Liu, X. Yu, J.J. Zhao, D.E. Slaughter, B.H. Arison, and K.P. Vyas In vitro metabolism of simvastatin in humans: identification of metabolizing enzymes and effect of the drug on hepatic P450s Drug Metabolism and Disposition 25 1997 1191 1199
19. W.C. Roberts The rule of 5 and the rule of 7 in lipidlowering by statin drugs American Journal of Cardiology 80 1997 106 107
20. H. Sakai, S. Kobayashi, K. Hamada, S. Iida, H. Akita, E. Tanaka, E. Uchida, and H. Yasuhara The effects of diltiazem on hepatic drug metabolizing enzymes in man using antipyrine, trimethadione and debrisoquine as model substrates British Journal of Clinical Pharmacology 31 1991 353 355
21. J. Shepherd Preventing coronary artery disease in the West of Scotland: implications for primary prevention American Journal of Cardiology 82 1998 57T 59T
22. D. Sutton, A.M. Butler, L. Nadin, and M. Murray Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites Journal of Pharmacology and Experimental Therapeutics 282 1997 294 300
23. The Scandinavian Simvastatin Survival Study (4S) Randomised trial of cholesterol lowering in 4444 patients with coronary artery disease Lancet 344 1994 1383 1389
24. A.M. Tonkin Management of the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study after the Scandinavian Simvastatin Survival Study (4S) American Journal of Cardiology 76 1995 107C 112C
25. S. Vickers, C.A. Duncan, I.W. Chen, A. Rosegay, and D.E. Duggan Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug Drug Metabolism and Disposition 18 1990 138 145
26. S. Vickers, C.A. Duncan, K.P. Vyas, P.H. Kari, B. Arison, S.R. Prakash, H.G. Ramjit, S.M. Pitzenberger, G. Stokker, and D.E. Duggan In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase Drug Metabolism and Disposition 18 1990 476 483
27. J.S. Wang, X. Wen, J.T. Backman, P. Taavitsainen, P.J. Neuvonen, and K.T. Kivisto Midazolam alpha-hydroxylation by human liver microsomes in vitro: inhibition by calcium channel blockers, itraconazole and ketoconazole Pharmacology and Toxicology 85 1999 157 161
28. D. Wood Asymptomatic individuals-risk stratification in the prevention of coronary heart disease British Medical Bulletin 59 2001 3 16
29. K.R. Yeo, W.W. Yeo, E.J. Wallis, and L.E. Ramsay Enhanced cholesterol reduction by simvastatin in diltiazem-treated patients British Journal of Clinical Pharmacology 48 1999 610 615
30. K.R. Yeo, and W.W. Yeo Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes British Journal of Clinical Pharmacology 51 2001 461 470